脑心通胶囊对冠心病高脂血症患者脂联素及血管内皮功能的影响

目的: 探讨脑心通胶囊对冠心病高脂血症患者的脂联素及血管内皮功能的控制。 方法: 将80例患者随机按数字法分为对照组和观察组各40例。两组均给予西医常规治疗,对照组加用阿托伐他汀钙片,20 mg/次,晚上睡前口服。观察组在对照组治疗的基础上加服脑心通胶囊,1.6 g/次,3次/d。疗程均为12周。检测治疗前后血清脂联素(APN)、血管性血友病因子(vWF)、血清一氧化氮(NO)、内皮素1(ET-1)、血栓素(TXB₂)及6-酮-前列腺素F-(1a)(6-Keto-PGF-1a),并检测血脂水平,进行心电图检查。 结果: 观察组降脂效果总有效率达95.0%,优于对照组的80.0%(P<0.01);观察组心电图疗效总有效率80.0%,优于对照组的55.0%(P<0.01);治疗后观察组胆固醇(TC),甘油三酯(TG)水平均明显下降并低于对照组(P<0.01);治疗后两组血清APN水平均升高,观察组上升更为显著(P<0.01);治疗后两组血清vWF均下降,观察组低于对照组(P<0.01);两组治疗后NO均升高,观察组高于对照组,ET-1均明显下降,观察组低于对照组(P<0.01);两组治疗后TXB₂ 均下降,观察组低于对照组,6-Keto-PGF_1a均上升,观察组高于对照组(P<0.01)。 结论: 脑心通胶囊能升高冠心病高脂血症患者APN水平,抑制炎症反应,通过改善ET/NO和TXA₂/PGI₂比例、下调vWF水平正性调节血管内皮功能,从而发挥抗动脉粥样硬化作用。

Influence of Naoxintong Capsule on Adiponectin and Endothelial Function of Coronary Heart Disease Patients with Hyperlipidemia

Objective: The discussed is to study the control of Naoxintong capsule on adiponectin and endothelial function of coronary heart disease patients with hyperlipidemia. Method: Eighty cases of patients were randomly divided into control group (40 cases) and observation group (40 cases) by digital method. Patients in two groups all took conventional western medicine treatment, atorvastatin, 20 mg/time, before sleeping at night orally. In addition, patients in observation group took Naoxintong capsule, 1.6 g/time, 3 times/day. The courses were all 12 weeks. serum adiponectin (APN), von Willebrand factor(vWF), serum nitric oxide (NO), endothelin 1(ET-1), thromboxane(TXB₂) and 6-ketone-prostaglandin F-(1a)(6-Keto-PGF-1a) were tested before and after treatment, as well as blood lipid level and the examination of the electrocardiogram. Result: The total effective rate of observation group was 95.0%, higher than that of control group 80.0% (P<0.01). The total effective rate of the electrocardiogram effect of observation group was 80.0%, superior to 55.0% in the control group (P<0.01). The levels of cholesterol(TC) and triglycerides(TG) decreased significantly and were lower than the control group (P<0.01). After treatment, the serum APN levels of both groups increased, while obvious increasing occurred in observation group (P<0.01). Serum vWF and TXB₂ of two groups decreased and observation group was lower than the control group (P<0.01). NO and 6-Keto-PGF-1a increased in both groups and observation group was higher than the control group(P<0.01).Obvious decreasing of ET-1 took place in both groups and observation group is lower than the control group (P<0.01). Conclusion: Naoxintong capsule can increase APN level of coronary heart disease patients with hyperlipidemia, inhibit inflammatory reaction, by improving the proportion of ET/NO and PGI₂/TXA₂, decreasing vWF level positive regulating endothelial function, and thus play a role of resistance to atherosclerosis.